Successful Third Trial Shows Efficacy in Easing Hot Flashes, Providing Relief Amid Pharmaceutical Setback
Germany’s Bayer said in a statement that a third Phase III trial with its elinzanetant drug candidate provided supporting data on efficacy and long-term safety.
Together with data from two earlier studies, Bayer would file requests for approval for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes, associated with menopause.
The readouts mark a slight turn of fortune for embattled Bayer, which in November aborted a large late-stage trial because a new anti-blood-clotting therapy did not work as hoped, derailing its most promising drug development project.
Bayer had previously estimated the blood-thinning drug could have peak annual sales of more than 5 billion euros ($5.5 billion), while menopause drug elinzanetant was given the potential of about a billion dollars or more per year.
In the race for non-hormonal menopausal symptoms relief drugs, Bayer is behind Japan’s Astellas (4503.T), opens new tab, which last year won U.S. and European approval for similar treatment Veoza, also known as fezolinetant.
Read More:Food for thought: Relationship between nutrition and cancer prevention
Yet another similar compound, developed by Acer Therapeutics , failed to ease hot flashes in a mid-stage trial last year.
